# Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer

> **NCT00049998** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 760 (—)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** topotecan

## Key facts

- **NCT ID:** NCT00049998
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-10
- **Primary completion:** 2004-04
- **Final completion:** —
- **Target enrollment:** 760 (—)
- **Last updated:** 2013-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00049998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00049998, "Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00049998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*